cybin.com Open in urlscan Pro
34.27.141.77  Public Scan

Form analysis
2 forms found in the DOM

Name: Sign up — POST

<form class="elementor-form" method="post" name="Sign up">
  <input type="hidden" name="post_id" value="365">
  <input type="hidden" name="form_id" value="4e9f6131">
  <input type="hidden" name="referer_title" value="Cybin - Changing Minds">
  <input type="hidden" name="queried_id" value="365">
  <div class="elementor-form-fields-wrapper elementor-labels-">
    <div class="elementor-field-type-email elementor-field-group elementor-column elementor-field-group-email elementor-col-60 elementor-field-required">
      <label for="form-field-email" class="elementor-field-label elementor-screen-only">Email Address</label><input size="1" type="email" name="form_fields[email]" id="form-field-email"
        class="elementor-field elementor-size-sm  elementor-field-textual" placeholder="Email Address" required="required" aria-required="true">
    </div>
    <div class="elementor-field-group elementor-column elementor-field-type-submit elementor-col-40 e-form__buttons">
      <button type="submit" class="elementor-button elementor-size-sm">
        <span>
          <span class=" elementor-button-icon">
          </span>
          <span class="elementor-button-text">Submit</span>
        </span>
      </button>
    </div>
  </div>
</form>

Name: Sign up — POST

<form class="elementor-form" method="post" name="Sign up">
  <input type="hidden" name="post_id" value="365">
  <input type="hidden" name="form_id" value="68059b4d">
  <input type="hidden" name="referer_title" value="Cybin - Changing Minds">
  <input type="hidden" name="queried_id" value="365">
  <div class="elementor-form-fields-wrapper elementor-labels-">
    <div class="elementor-field-type-email elementor-field-group elementor-column elementor-field-group-email elementor-col-60 elementor-field-required">
      <label for="form-field-email" class="elementor-field-label elementor-screen-only">Email Address</label><input size="1" type="email" name="form_fields[email]" id="form-field-email"
        class="elementor-field elementor-size-sm  elementor-field-textual" placeholder="Email Address" required="required" aria-required="true">
    </div>
    <div class="elementor-field-group elementor-column elementor-field-type-submit elementor-col-40 e-form__buttons">
      <button type="submit" class="elementor-button elementor-size-sm">
        <span>
          <span class=" elementor-button-icon">
          </span>
          <span class="elementor-button-text">Submit</span>
        </span>
      </button>
    </div>
  </div>
</form>

Text Content

NYSE AMERICAN:CYBN
NEO:CYBN

NYSE AMERICAN:CYBN
NEO:CYBN

 * Our Work
   * Development Pipeline
   * Partnerships
   * Scientific Publications
   * Intellectual Property
   * EMBARK
   * CYB003
   * CYB004
 * Investors
   * Overview
   * News
   * Events & Presentations
   * Stock Info
   * Financials
   * Governance
 * About Us
   * Our Team
   * Our Focus
   * Join Us
   * Contact Us

Menu
 * Our Work
   * Development Pipeline
   * Partnerships
   * Scientific Publications
   * Intellectual Property
   * EMBARK
   * CYB003
   * CYB004
 * Investors
   * Overview
   * News
   * Events & Presentations
   * Stock Info
   * Financials
   * Governance
 * About Us
   * Our Team
   * Our Focus
   * Join Us
   * Contact Us








CHANGING MINDS


REVOLUTIONIZING MENTAL HEALTHCARE


CHANGING MINDS

REVOLUTIONIZING MENTAL
HEALTHCARE


LATEST UPDATES


Read More

CYBIN ANNOUNCES POSITIVE DATA FROM ITS CYB003 PHASE 1/2A TRIAL AND PROVIDES
UPDATE ON ITS CYB004 DEVELOPMENT PROGRAM

Read More

CYBIN ANNOUNCES APPROVAL OF FIRST-IN-HUMAN DOSING OF ITS PROPRIETARY DMT
MOLECULE CYB004

CYBIN ANNOUNCES PROMISING RESULTS FROM SPONSORED KERNEL FLOW® FEASIBILITY STUDY
MEASURING PSYCHEDELIC EFFECTS ON THE BRAIN


MISSED OUR VIRTUAL R&D DAY?



Click here to watch the replay



MISSED OUR VIRTUAL R&D DAY?

Click here to watch the replay
What We do


WE’RE ON A MISSION TO REVOLUTIONIZE MENTAL HEALTHCARE.

At Cybin, we’re on a mission to revolutionize mental healthcare by engineering
proprietary drug discovery platforms, innovative drug delivery systems, novel
formulation approaches and treatment regimens to address the unmet needs of
patients across a multitude of mental health issues.

We are working with a network of world-renowned partners and pioneers in the
field to create safe and effective psychedelic-based therapies. Together, we
believe we can discover, develop and commercialize novel therapies that will
transform the mental health treatment landscape.


Watch Video

Sign up to receive news and updates.
Email Address
Submit

What We do


WE’RE ON A MISSION TO REVOLUTIONIZE MENTAL HEALTHCARE.

At Cybin, we’re on a mission to revolutionize mental healthcare by engineering
proprietary drug discovery platforms, innovative drug delivery systems, novel
formulation approaches and treatment regimens to address the unmet needs of
patients across a multitude of mental health issues.

We are working with a network of world-renowned partners and pioneers in the
field to create safe and effective psychedelic-based therapies. Together, we
believe we can discover, develop and commercialize novel therapies that will
transform the mental health treatment landscape.


Watch Video

Sign up to receive news and updates.
Email Address
Submit


LED BY SCIENCE

Our strategy is to combine novel psychedelic molecules with controllable drug
delivery systems through our proprietary deuterated process. With our approach,
we are engineering next-generation psychedelic, patent-protected, commercially
scalable drug candidates to further evolve mental health treatments.

Novel Second-Generation Psychedelics based on well-known scaffolds including
Psilocybin, DMT, MDMA with improved bioavailability.

Leveraging cutting-edge Neuroimaging technology to generate quantitative data to
better understand psychedelic therapies.

Developing ground-breaking psychotherapy that integrates leading clinical
approaches to promote supportive healing with psychedelic medicine.

Learn More
1


3 active drug programs targeting Major Depressive Disorder (CYB003), Alcohol Use
Disorder (CYB003), Anxiety Disorders (CYB004) and Neuroinflammation (CYB005).

1


250+ pre-clinical studies completed and progressing lead programs toward FDA IND
filings.

> 1


>50 granted or pending patent applications filed across 6 patent families.  




BACKED BY AN
EXPERIENCED TEAM

Deep-rooted pharmaceutical and regulatory expertise across psychiatry and
psychedelics drug development. Scientific leadership that includes work in
addiction and psychedelics, oversight of 60+ IND programs with the FDA as well
as success in developing multiple widely used commercially available
prescription drugs.

Our Team


RECENT NEWS

May 9, 2022
Press Release

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility
Study Measuring Ketamine’s Effects on the Brain

April 21, 2022
Press release
April 13, 2022
PRESS RELEASE

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over
Intravenous and Inhaled DMT

February 15, 2022
Press Release

The Chopra Foundation Announces Partnership with Cybin Inc. to Increase
Education and Awareness of the Potential Use of Psychedelics in Supporting
Well-Being and Mental Health

Read More
NEO:CYBN $0.475 CAD 0.01 2.151% view stock »
NYSE:CYBN $0.367 USD -0.004 -1.078% view stock »



IN THE PRESS

Previous
Next


 * Our Work
   * Development Pipeline
   * Partnerships
   * Scientific Publications
   * Intellectual Property
   * EMBARK
   * CYB003
   * CYB004
 * Investors
   * Overview
   * News
   * Events & Presentations
   * Stock Info
   * Financials
   * Governance
 * About Us
   * Our Team
   * Our Focus
   * Join Us
   * Contact Us





Copyright Cybin Corp. © 2021 . All rights reserved.        Privacy Policy |
Cybin IRL Limited Employee Privacy Policy | Cybin IRL Limited Privacy Notice